Teva CEO Schultz took a big pay cut last year—but he bagged a contract extension, too

Teva has undergone a massive transformation in the past two years after a $3 billion restructuring fundamentally reshaped the Israeli drugmaker's operations. The man who led that charge, CEO Kåre Schultz, saw a big pay cut last year but will take solace with an extension that will keep him on board until at least 2023.